| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: =98.70%
| Targets |
Methylprednisolone sodium succinate targets the glucocorticoid receptor, a nuclear receptor that regulates gene expression. By binding to this receptor, it alters the transcription of target genes, leading to anti-inflammatory and immunosuppressive effects. It reduces the production of pro-inflammatory cytokines, reduces the number of circulating lymphocytes, and induces cell differentiation and apoptosis. It is a potent anti-inflammatory agent.
|
|---|---|
| ln Vitro |
In vitro, methylprednisolone sodium succinate binds to the glucocorticoid receptor and modulates gene expression. It reduces the production of pro-inflammatory cytokines in immune cells. It also induces apoptosis in sensitive tumor cell populations. These activities demonstrate its potent anti-inflammatory and immunosuppressive effects.
|
| ln Vivo |
In vivo, methylprednisolone sodium succinate is used for cardiac, allergic, and hypoxic emergencies. It is used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, and eye conditions. It is a widely used corticosteroid for various inflammatory and autoimmune diseases.
|
| Enzyme Assay |
The in vitro receptor binding assay for methylprednisolone sodium succinate typically involves radioligand displacement studies using the glucocorticoid receptor. The compound's affinity for the receptor is determined by measuring its ability to displace a specific radiolabeled ligand. These cell-free assays provide a direct measure of the compound's binding affinity for the glucocorticoid receptor.
|
| Cell Assay |
In vitro cellular assays for methylprednisolone sodium succinate assess its effects on gene expression and cytokine production. Immune cells are treated with methylprednisolone, and the expression of pro-inflammatory cytokines is measured. Its effects on lymphocyte viability and apoptosis can also be assessed. These assays demonstrate the compound's functional activity in a relevant cellular context.
|
| Animal Protocol |
In vivo animal studies for methylprednisolone sodium succinate have been conducted in various animal models of inflammation and autoimmune diseases to evaluate its efficacy. However, its clinical efficacy has been established in human use for various inflammatory conditions.
|
| ADME/Pharmacokinetics |
Methylprednisolone sodium succinate is administered intravenously or intramuscularly for rapid onset of action. It is a water-soluble salt of methylprednisolone. It is metabolized in the liver and excreted in urine. It has a slightly longer half-life than prednisolone. Its pharmacokinetic properties support its use in acute and chronic conditions.
|
| Toxicity/Toxicokinetics |
Methylprednisolone sodium succinate has a well-established safety profile but is associated with significant adverse effects with long-term use. Common adverse effects include weight gain, hyperglycemia, osteoporosis, and immunosuppression. It should be used with caution in patients with diabetes, hypertension, and infections. Its safety has been established through extensive clinical use.
|
| References |
|
| Additional Infomation |
Methylprednisolone sodium succinate is a corticosteroid. It is the sodium salt of the synthetic glucocorticoid receptor agonist and possesses immunosuppressive and anti-inflammatory effects. In vivo, methylprednisolone sodium succinate is converted to active prednisolone, activating glucocorticoid receptor-mediated gene expression. This includes inducing the synthesis of the anti-inflammatory protein IκB-α and inhibiting the synthesis of nuclear factor κB (NF-κB). Consequently, the production of pro-inflammatory cytokines such as IL-1, IL-2, and IL-6 is downregulated, and the activation of cytotoxic T lymphocytes is suppressed. Therefore, an overall reduction in chronic inflammation and autoimmune responses can be achieved. Methylprednisolone water-soluble esters are used to treat cardiac, allergic, and hypoxic emergencies. See also: Methylprednisolone (containing the active moiety).
Methylprednisolone sodium succinate is a synthetic glucocorticoid used for the treatment of various inflammatory and autoimmune conditions. It binds to the glucocorticoid receptor, alters gene expression, and reduces pro-inflammatory cytokine production. It is commonly used in the treatment of asthma, rheumatoid arthritis, and multiple sclerosis. It is available as a prescription medication. |
| Molecular Formula |
C26H33NAO8
|
|---|---|
| Molecular Weight |
496.53
|
| Exact Mass |
496.207
|
| Elemental Analysis |
C, 62.89; H, 6.70; Na, 4.63; O, 25.78
|
| CAS # |
2375-03-3
|
| Related CAS # |
Methylprednisolone succinate;2921-57-5
|
| PubChem CID |
23680530
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
689.6ºC at 760mmHg
|
| Flash Point |
230.7ºC
|
| LogP |
0.884
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
35
|
| Complexity |
988
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@@]12[C@](C(COC(CCC([O-])=O)=O)=O)(O)CC[C@@]1([H])[C@]3([H])C[C@H](C)C4=CC(C=C[C@]4(C)[C@@]3([H])[C@@H](O)C2)=O.[Na+]
|
| InChi Key |
FQISKWAFAHGMGT-SGJOWKDISA-M
|
| InChi Code |
InChI=1S/C26H34O8.Na/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/q+1/p-1/t14-,16-,17-,19-,23+,24-,25-,26-/m0./s1
|
| Chemical Name |
Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-6-alpha-methyl-, 21- (hydrogen succinate), monosodium salt
|
| Synonyms |
Methylprednisolone sodium succinate; U 9088; U-9088; U9088
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL ~(100.70 mM)
Ethanol : ~100 mg/mL DMSO :25~100 mg/mL (50.35~201.39 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.08 mg/mL (4.19 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0140 mL | 10.0699 mL | 20.1398 mL | |
| 5 mM | 0.4028 mL | 2.0140 mL | 4.0280 mL | |
| 10 mM | 0.2014 mL | 1.0070 mL | 2.0140 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02425813 | Withdrawn | Drug: Budesonide Drug: Methylprednisolone Sodium Succinate |
Acute Graft Versus Host Disease Intestinal Graft Versus Host Disease |
Wake Forest University Health Sciences | 2015-10 | Phase 2 |
| NCT05649878 | Completed | Drug: Evaluation of bioavailability of methylprednisolone succinate administered intravenously Drug: Evaluation of bioavailability of methylprednisolone succinate administered intranasally |
Healthy Subjects Intranasal Administration Intravenous Administration Methylprednisone Administration |
Edda Sciutto Conde | 2021-11-05 | Not Applicable |
| NCT01167946 | Completed | Drug: methylprednisolone sodium succinate Drug: methylprednisolone sodium succinate Drug: methylprednisolone sodium succinate |
Alopecia Totalis Alopecia Universalis Ophiasic Alopecia |
King Saud University | 2003-01 | Phase 4 |
| NCT06360458 | Recruiting | Drug: Methylprednisolone sodium succinate Drug: Placebo (Methylprednisolone sodium succinate simulant) |
Acute Ischemic Stroke | Wan-Jin Chen | 2024-08-01 | Phase 3 |
| NCT04343729 | Completed | Drug: Methylprednisolone Sodium Succinate Drug: Placebo solution |
SARS-CoV Infection Severe Acute Respiratory Syndrome (SARS) Pneumonia |
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado |
2020-04-18 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA